New Alzheimer’s drug raises hopes and questions

New Alzheimer's drug raises hopes and questions

The FDA has approved Leqembi, the first disease-modifying treatment for early-stage Alzheimer’s and a precursor condition, mild cognitive impairment. Medicare said it will pay for the therapy. Medical centers across the country are scrambling to finalize policies and procedures for providing medications to patients, possibly by the end of summer or early fall. It’s a … Read more